(NVO) Novo Nordisk A/S Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NVO) Novo Nordisk A/S Complete Analysis Pack
Novo Nordisk’s Business Model Canvas, Simplified
Unlock the strategic logic behind Novo Nordisk A/S’s business model with a clear, concise Business Model Canvas. This snapshot shows how the company creates value, reaches patients, and sustains growth in a highly competitive market. Get the full canvas for deeper insights, sharper benchmarking, and smarter decision-making.
Partnerships
UNICEF childhood obesity partnership
Novo Nordisk’s UNICEF partnership supports community-based obesity prevention and health education beyond prescription sales. This matters: WHO says over 390 million children and adolescents aged 5-19 were living with overweight in 2022, and UNICEF works in 190+ countries and territories, giving Novo Nordisk reach for local prevention work.
Valo Health cardiometabolic alliance
Novo Nordisk A/S uses the Valo Health, Inc. R&D alliance to find and advance new cardiometabolic drug programs, adding external innovation to its pipeline. This matters in a market where cardiometabolic disease drives major unmet need: cardiovascular disease caused about 19.8 million deaths in 2022, supporting faster early-stage discovery.
The partnership helps Novo Nordisk A/S widen its research base beyond internal work and speed target selection with Valo Health, Inc. technology, which can improve pipeline depth in a high-value area where Novo Nordisk A/S spent DKK 40.1 billion on R&D in 2024.
Healthcare providers and specialist clinics
Healthcare providers and specialist clinics are key partners for physicians, endocrinologists, hematologists, and hospital networks that prescribe and administer Novo Nordisk A/S therapies. In 2025, this channel still mattered most because chronic and rare-disease medicines depend on clinical adoption, patient monitoring, and ongoing treatment follow-up.
Suppliers of APIs and device components
Novo Nordisk depends on suppliers of active pharmaceutical ingredients, pens, needles, packaging, and other device parts to keep high-volume drug and device output steady. These partnerships matter because quality control and supply continuity directly affect the company’s ability to serve global demand for diabetes and obesity treatments.
- Secure API and device supply
- Protect quality and continuity
- Support large-scale production
Distributors, wholesalers, and logistics firms
Novo Nordisk A/S depends on distributors, wholesalers, and logistics firms to move medicines and devices across Europe, the Middle East, Africa, Asia, and North America, reaching pharmacies, hospitals, and public procurement systems in more than 170 countries. Cold-chain handling matters because temperature excursions can damage biologics, and last-mile delivery keeps diabetes and obesity therapies on time.
- Cold chain protects product quality
- Wholesalers widen market access
- Last mile supports patient supply
Novo Nordisk’s Key Partners Fuel R&D, Prevention, and Supply Reach
Novo Nordisk A/S relies on UNICEF, Valo Health, Inc., healthcare providers, and suppliers to extend prevention, speed R&D, and keep drug and device supply stable. In 2024, Novo Nordisk A/S spent DKK 40.1 billion on R&D, while its products reached more than 170 countries through distributors and logistics partners.
| Partner | Role | Data |
|---|---|---|
| Valo Health, Inc. | R&D alliance | Pipeline expansion |
| UNICEF | Prevention reach | 190+ countries |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Novo Nordisk A/S, covering its 9 blocks, value drivers, and competitive strengths.
Customizable Excel Spreadsheet
Quickly shows how Novo Nordisk A/S reduces patient and provider pain points in one editable business model snapshot.
Reference Sources
Gives a credible source trail for Novo Nordisk A/S, helping decision-makers verify assumptions fast and trust the analysis.
Activities
Research and development in chronic disease
Novo Nordisk A/S uses research and development to discover and advance therapies in diabetes, obesity, cardiovascular, and rare disease, covering preclinical work, formulation, and translational science. R&D is the engine for pipeline renewal and long-term growth; the company spent DKK 40.1bn on R&D in 2024, up from DKK 33.7bn in 2023.
Clinical trials and regulatory submissions
Clinical trials and regulatory submissions are central to Novo Nordisk A/S, with large phase 3 programs testing safety, efficacy, and dose across global sites before filings with the FDA, EMA, and other regulators. This work also supports label expansion and lifecycle management, which is vital as R&D spending stays above DKK 20 billion a year.
Manufacturing and quality control
Manufacturing and quality control keep Novo Nordisk A/S medicines, pens, needles, and delivery tools flowing through a global network. The company runs strict biologics and sterile-production systems; in 2024, it lifted capital spending to DKK 75.4 billion to expand output and protect supply reliability.
That scale matters because supply must stay stable as demand rises, and any batch failure can hit patients fast. For a biologics maker, tight process control is not support work; it is a core value driver.
Commercialization and medical education
Commercialization and medical education are central to Novo Nordisk A/S launches, market access, and HCP engagement, because prescription medicines need clear science and therapy training. In 2024, the Company reported DKK 290.4 billion in sales, showing how well this engine supports adoption in chronic-care markets.
- Launch support and payer access
- Scientific education for prescribers
- Drives uptake in chronic care
Digital health and connected-device development
In 2025, Novo Nordisk A/S used smart insulin pens and the Dose Check application to support dosing guidance and adherence. This key activity pushes the business beyond medicines alone and into day-to-day care support for people using insulin.
- Smart pens track doses
- Dose Check supports guidance
- Improves adherence support
- Extends care beyond drugs
Novo Nordisk boosts R&D and capacity to fuel growth
Novo Nordisk A/S focuses on discovery, clinical testing, and regulatory filings in diabetes, obesity, cardiovascular, and rare diseases; R&D spend was DKK 40.1bn in 2024. It also runs sterile manufacturing and quality control, with capital spending at DKK 75.4bn in 2024 to lift output and protect supply.
| Activity | 2024 |
|---|---|
| R&D | DKK 40.1bn |
| Capex | DKK 75.4bn |
Full Document Unlocks After Purchase
Business Model Canvas
This Novo Nordisk A/S Business Model Canvas preview is the exact document you’ll receive after purchase, not a sample or mockup. The layout, structure, and content shown here match the final file you’ll download. Buy with confidence—what you see is what you get, ready to use, edit, and share.
Resources
Global pharmaceutical R and D capability
Nova Nordisk A/S uses its global pharmaceutical R and D capability to power scientific teams and development sites across diabetes, obesity, and rare disease. This resource is the core engine for new pipeline assets and for improving existing medicines through clinical, regulatory, and formulation work.
Manufacturing network and quality systems
Novo Nordisk A/S relies on its global manufacturing network and quality systems to produce insulin, GLP-1 medicines, and devices at scale, with release data tightly controlled across sites in Denmark, the US, and China. In 2024, the company reported DKK 290.4 billion in net sales, so consistent, validated production is a core supply-chain asset.
Patents and proprietary drug know-how
Novo Nordisk A/S uses patents and proprietary drug know-how to protect molecules, formulations, and delivery systems, which helps defend premium brands in crowded diabetes and obesity markets. This IP moat supports long product life cycles by keeping follow-on copycats out and preserving pricing power.
Specialized devices and digital platforms
Novo Nordisk A/S relies on insulin pens, growth hormone pens, injection needles, smart pens, and the Dose Check app to make dosing simpler and more accurate. These tools support the company’s integrated care model, which mattered as it guided 2025 sales growth of 16% to 24% at constant exchange rates.
- Supports precise drug delivery
- Improves treatment guidance
- Strengthens integrated care
Brand, scale, and 1923 heritage
Novo Nordisk A/S leans on a brand built since 1923 in Bagsværd, Denmark. That long heritage and global scale support trust with regulators, payers, and doctors, helping the Company keep access in key markets.
In 2024, Novo Nordisk reported DKK 290.4 billion in revenue and employed about 77,000 people, showing the reach behind that trust.
- Founded in 1923
- Headquartered in Bagsværd
- DKK 290.4 billion revenue
- About 77,000 employees
Novo Nordisk’s R&D, IP, and scale drive growth
Novo Nordisk A/S’s key resources are its R and D base, global manufacturing network, and patent-protected drug know-how. Together they supported DKK 290.4 billion in 2024 net sales and its 2025 constant-currency sales-growth guidance of 16% to 24%.
The Company also relies on delivery devices, smart pens, and the Dose Check app to support dosing and patient use. Its brand, built since 1923 and backed by about 77,000 employees, helps protect market trust and access.
| Resource | Data point |
|---|---|
| Net sales | DKK 290.4 billion in 2024 |
| Employees | About 77,000 |
| 2025 sales guidance | 16% to 24% at constant exchange rates |
Value Propositions
Therapies for diabetes care
Novo Nordisk’s diabetes care therapies serve millions of patients with chronic disease control and long-term treatment support. In FY2024, the Company reported DKK 290.4 billion in sales, with diabetes and obesity care still the core of its business; Ozempic, Rybelsus, and Tresiba anchor its position in large-scale diabetes management.
Medicines for obesity care
Novo Nordisk A/S uses prescription obesity medicines to treat obesity as a chronic disease, placing it alongside diabetes in its core business. This broadens the offer beyond glucose control; with over 1 billion people living with obesity worldwide, the category gives the company a large, recurring demand base.
Rare disease treatments
Novo Nordisk A/S uses its rare disease portfolio for therapies in hemophilia and uncommon endocrine disorders, plus hormone replacement solutions for small patient groups with specialized needs. Hemophilia affects about 1 in 10,000 births, so these products target high-unmet-need niches where clinical expertise and long-term care matter most.
Delivery devices and injection tools
Novo Nordisk A/S uses delivery devices and injection tools such as insulin pens, growth hormone pens, and needles to make self-injection easier outside hospitals. This matters at scale: Novo Nordisk reported DKK 290.4 billion in sales in 2024, showing how closely its medicine portfolio and practical delivery support work together.
- Supports home treatment
- Improves injection ease
- Complements medicine sales
Smart dosing and digital support
Smart dosing and digital support in Novo Nordisk A/S use connected pens and the Dose Check application to guide insulin delivery, log doses, and support safer day-to-day use. The value is simple: more convenience for patients, better dose visibility, and fewer missed or uncertain injections.
- Connected pens track insulin doses.
- Dose Check adds safety support.
- Digital tools improve treatment use.
Novo Nordisk: Chronic Care at Scale, Powered by Diabetes and Obesity
Novo Nordisk A/S value props center on chronic care at scale: diabetes and obesity medicines, rare disease therapies, plus delivery devices and digital dose support that make home treatment easier. FY2024 sales were DKK 290.4 billion, with diabetes and obesity care the core growth engine.
| Value prop | Data |
|---|---|
| Core care | DKK 290.4 billion FY2024 sales |
| Obesity reach | 1 billion+ people affected |
Customer Relationships
Physician-prescribed treatment model
Novo Nordisk A/S uses a physician-prescribed model, so most patients receive therapies through doctors and other healthcare professionals, not direct consumer sales. This fits regulated pharma markets and supports reach at scale: Novo Nordisk A/S reported net sales of DKK 290.4 billion in 2024, driven by prescription medicines like GLP-1 and insulin products.
Long-term chronic-care support
Novo Nordisk A/S relies on long-term chronic-care support because diabetes affects about 589 million adults worldwide, and obesity tops 1 billion, so treatment, dose checks, and refill follow-up often continue for years. That makes continuity central: repeated monitoring and adherence support help keep patients engaged across lifelong therapy.
Patient education and adherence support
Patient education and adherence support help train patients on dose use, injection technique, and therapy routines, so Novo Nordisk A/S medicines and pens are used correctly. That matters because better teaching supports adherence and persistence over time, which is central in chronic care where long-term use drives outcomes.
Medical affairs and scientific engagement
Novo Nordisk uses medical affairs and scientific engagement to speak with doctors, hospitals, and clinical experts on complex therapies, including its GLP-1 and insulin portfolio. This evidence-based dialogue helps build trust, support appropriate use, and align treatment with clinical data.
In FY2024, Novo Nordisk reported DKK 290.4 billion in sales, showing the scale that makes clear, science-led communication critical.
- Supports evidence-based use
- Builds trust with clinicians
- Helps explain complex therapies
Digital engagement through apps and smart devices
Novo Nordisk A/S uses digital engagement through apps and smart devices to keep connected-care touchpoints active after the clinic visit. Tools like Dose Check can send reminders and dosing guidance, which helps patients stay on track and strengthens daily relationship management.
- Reminder support between visits
- Dosing guidance in real time
- Better adherence to treatment
Novo Nordisk Builds Lasting Loyalty Through Clinical Care and Digital Support
Novo Nordisk A/S keeps customer ties clinical and continuous: doctors lead prescribing, while patient education, refill support, and digital tools help people stay on therapy. With FY2024 net sales of DKK 290.4 billion, these relationships are built for long-term chronic care.
| Touchpoint | Role |
|---|---|
| Physicians | Prescribing and monitoring |
| Patients | Adherence and dose support |
| Digital tools | Reminders and guidance |
Medical affairs and scientific dialogue also support trust with clinics and hospitals, helping Novo Nordisk A/S explain complex GLP-1 and insulin therapies clearly.
Channels
Hospitals and outpatient clinics
Hospitals and outpatient clinics give Novo Nordisk direct access to prescribing specialists and monitored starts, which matters most in rare disease and complex chronic care. This channel fits the company’s scale in 2025, when sales reached DKK 290.4 billion and treatment demand kept moving into specialist-led care.
Retail and specialty pharmacies
Retail and specialty pharmacies are a core channel for Novo Nordisk A/S because they dispense prescription medicines and devices directly to patients, including recurring fills for managed therapies like obesity and diabetes care. In 2025, Novo Nordisk A/S generated DKK 290.4 billion in sales, showing how broad pharmacy access helps support scale and repeat demand.
Wholesalers and distributors
Wholesalers and distributors are a core route for Novo Nordisk A/S, moving medicines from manufacturing sites into national and regional markets across its global footprint of more than 170 countries. They help keep supply local, fast, and reliable, which matters when the company serves millions of patients with diabetes and obesity treatments.
Public procurement and tenders
Public procurement and tenders are key for Novo Nordisk A/S in hospital and public payer markets, where one buyer can steer access for millions of patients. In publicly funded systems, procurement still covers about 80% of health spending in Europe, so tender wins can shape volume and pricing fast.
- Targets governments and health systems
- Drives access in many countries
- Most important in funded care systems
Digital websites and patient applications
Novo Nordisk A/S uses digital websites and patient applications to give online product guidance, dosing support, and education for patients and clinicians, while also backing connected-device tools like smart pens. In 2024, Novo Nordisk A/S reported DKK 290.4 billion in sales, showing the scale that makes digital support a key channel.
- Educate patients and clinicians online
- Support use and adherence tools
- Reinforce connected-device offers
Novo Nordisk’s Global Channels Fuel Growth Across 170+ Markets
Novo Nordisk A/S reaches patients through hospitals, outpatient clinics, pharmacies, wholesalers, and public tenders, which supports specialist starts and repeat fills for diabetes and obesity drugs. In 2025, sales were DKK 290.4 billion, and the company sold in more than 170 countries.
| Channel | Role | 2025 data |
|---|---|---|
| Hospitals | Specialist starts | Core for rare and complex care |
| Pharmacies | Repeat dispensing | Supports recurring demand |
| Tenders | Public access | Important in funded systems |
Customer Segments
People living with diabetes
People living with diabetes are Novo Nordisk A/S’s core patient base, and diabetes care remains the biggest business line. The International Diabetes Federation estimated 589 million adults were living with diabetes in 2025, and these patients need long-term glucose-lowering medicine, regular monitoring, and steady refill use.
Adults with obesity
Adults with obesity are Novo Nordisk A/S’s core chronic-care segment: more than 1 billion people worldwide live with obesity, and the company’s obesity care sales rose sharply as Wegovy demand expanded in 2024. This is clinically important and commercially large because treatment is long term, so recurring use can support durable revenue.
Patients with rare blood disorders
Novo Nordisk A/S serves patients with rare blood disorders, mainly in hematology, where needs are highly specialized and treatment volumes stay small but medically critical. Hemophilia A affects about 1 in 5,000 male births and hemophilia B about 1 in 25,000, so this segment is niche but life-changing.
Patients with rare endocrine conditions
Patients with rare endocrine conditions are a niche but high-need segment for Novo Nordisk A/S, covering uncommon hormone disorders that often need specialist-led care and lifelong replacement therapy. This fits the company’s rare disease focus, where treatment is typically chronic, protocol-driven, and managed through endocrinology centers.
- Specialist-managed, low-volume care
- Hormone replacement often needed
- Aligns with rare disease portfolio
Healthcare systems, payers, and providers
Healthcare systems, payers, and providers are Novo Nordisk A/S’s key institutional buyers and gatekeepers. Reimbursement and formulary access decide uptake, so hospital and public health system coverage can move demand faster than direct consumer pull.
- Access is payer-led.
- Formulary rules shape adoption.
- Hospitals drive volume.
Novo Nordisk's Huge Global Patient Markets in 2025
Novo Nordisk A/S serves four main customer groups: diabetes patients, obesity patients, rare disease patients, and the payers and providers that decide access. In 2025, the International Diabetes Federation estimated 589 million adults had diabetes, and over 1 billion people worldwide lived with obesity.
| Segment | 2025 scale |
|---|---|
| Diabetes | 589m adults |
| Obesity | 1bn+ people |
| Rare disease | Low-volume, specialist care |
Cost Structure
Research and development spend
Research and development is a major cost for Novo Nordisk A/S, funding discovery, preclinical work, and clinical trials that feed pipeline growth and regulatory approvals. It is also one of the company’s biggest spend lines because new therapies need years of testing before they can reach the market.
Manufacturing and device production costs
Manufacturing and device production costs are high for Novo Nordisk A/S because drug substance, fill-finish, pens, and needles rely on sterile biologic lines, which need heavy capex and tight QA. In 2024, Novo Nordisk reported DKK 290.4 billion in sales, and that scale still demands costly, controlled output across its diabetes and obesity portfolio.
Sales, marketing, and medical education
Novo Nordisk uses this spend to fund field teams, congress presence, and HCP education, which matters in prescription markets that need scientific promotion and market access work. In 2025, this area remained a multi-billion-DKK cost line, supporting faster uptake of products like Wegovy and Ozempic across regions.
Regulatory, compliance, and pharmacovigilance
Regulatory, compliance, and pharmacovigilance at Novo Nordisk A/S cover approvals, safety monitoring, and adverse-event reporting across global markets. In 2024, Novo Nordisk reported DKK 290.4 billion in revenue and DKK 128.3 billion in operating profit, which shows the scale needed to fund these controls and protect product quality and patient safety.
- Supports EMA and FDA approvals
- Funds safety surveillance and reporting
- High fixed cost for global compliance
- Protects patients and product quality
Distribution, logistics, and administrative overhead
Distribution, logistics, and administrative overhead cover Novo Nordisk A/S's warehousing, cold-chain transport, and corporate support. In 2024, the Company reported DKK 290.4bn in revenue, so global supply chains, regional hubs, and headquarters functions add real cost and coordination pressure.
- Warehousing and cold-chain transport
- Global supply chain complexity
- Headquarters and regional overhead
Novo Nordisk’s Cost Base: R&D Heavy, Manufacturing Intensive
Novo Nordisk A/S cost structure is dominated by R&D, biologics manufacturing, and global commercialization, so spend stays heavy before revenue lands. The Company’s scale in 2025 means compliance, cold chain, and admin costs also stay material.
| Cost line | Core driver |
|---|---|
| R&D | Pipeline, trials, approvals |
| Manufacturing | Sterile biologics, pens |
| SG&A | Sales, access, education |
| Compliance | Safety, quality, reporting |
Revenue Streams
Prescription medicine sales in diabetes care
Prescription diabetes medicines are a core revenue stream for Novo Nordisk A/S, anchored by long-term use in large, chronic patient pools. In 2024, the Company reported DKK 290.4 billion in sales, while the IDF estimated 589 million adults were living with diabetes worldwide, keeping demand for insulin and GLP-1 therapies strong.
Prescription medicine sales in obesity care
Prescription medicine sales in obesity care, led by Wegovy, are now a core revenue stream for Novo Nordisk A/S. Obesity care sales rose sharply in 2024 and helped lift total sales to DKK 290.4 billion, adding growth beyond diabetes and making this segment increasingly strategic in the portfolio.
Rare disease medicine sales
Novo Nordisk A/S rare disease medicines, mainly for hemophilia and endocrine conditions such as growth hormone deficiency, serve a narrow patient base but carry premium pricing. In 2024, the rare disease business generated about DKK 18.8 billion in sales, making it a high-value niche stream.
Device and consumable sales
Novo Nordisk A/S earns device and consumable revenue from insulin pens, growth hormone pens, and injection needles, so each medicine sale can also pull through hardware and refill demand. In 2025, this model stayed tied to chronic-use therapies, where recurring needle purchases and pen replacements support repeat sales.
- Insulin and growth hormone delivery devices
- Needles create recurring demand
- Revenue follows medicine use
Collaboration and partnership income
Novo Nordisk A/S uses collaboration and partnership income for alliance fees and research deals. The Valo Health pact, announced in 2023, included a USD 60 million upfront payment and up to USD 2.7 billion in milestones, showing how this stream can fund external innovation and pipeline growth.
- Alliance fees and research payments
- Milestone-linked upside
- Supports pipeline expansion
In 2025, Novo Nordisk A/S reported DKK 290.4 billion in revenue, with partnership income a small but strategic line that can add non-product cash flow.
Novo Nordisk 2025 Revenue: Diabetes, Obesity, and Rare Disease Power Growth
Novo Nordisk A/S revenue in 2025 came mainly from diabetes and obesity drugs, with rare disease and device sales adding recurring, high-margin cash flow. Total 2025 sales were DKK 290.4 billion, while rare disease contributed about DKK 18.8 billion.
| Stream | 2025 |
|---|---|
| Total sales | DKK 290.4bn |
| Rare disease | DKK 18.8bn |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.